

GLAXOSMITHKLINE PLC

Form 6-K

July 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
Chief Executive Officer
 - b) Position/status
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s)	Volume(s)
£16.18	70.538 (personal contribution)
£16.18	174.682 (personal contribution)
£16.18	190.188 (personal contribution)
£16.18	70.538(personal contribution)
£16.18	174.669 (personal contribution)
£16.18	190.176 (personal contribution)
 - c) Price(s) and volume(s)

£16.18	70.538 (matching shares)
£16.18	174.682 (matching shares)
£16.18	190.188 (matching shares)
£16.18	70.538 (matching shares)
£16.18	174.669 (matching shares)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.18 190.176 (matching shares)

Aggregated information

- d) Aggregated volume Price 1,741.582
 £16.18
 e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
 President, Global Manufacturing & Supply
 b) Position/status
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
- b) Nature of the transaction
- | Price(s) | Volume(s) |
|----------|---------------------------------|
| £16.18 | 51.658 (personal contribution) |
| £16.18 | 118.682 (personal contribution) |
| £16.18 | 99.029 (personal contribution) |
| £16.18 | 51.658 (personal contribution) |
- c) Price(s) and volume(s)
- | | |
|--------|--------------------------------|
| £16.18 | 99.017 (personal contribution) |
| £16.18 | 51.658 (matching shares) |
| £16.18 | 118.682 (matching shares) |
| £16.18 | 99.029 (matching shares) |
| £16.18 | 51.658 (matching shares) |

£16.18 99.017 (matching contribution)

Aggregated information

- d) Aggregated volume Price 840.088
 £16.18
 e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Debruyne
 b) Position/status President, Global Vaccines
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
 b) Nature of the transaction Price(s) Volume(s)

£16.18 166.446 (personal contribution)

- c) Price(s) and volume(s) £16.18 166.433 (personal contribution)

£16.18 166.446 (matching shares)

£16.18 166.433 (matching shares)

Aggregated information

- d) Aggregated volume Price 665.758
 £16.18
 e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr S Dingemans
 - b) Position/status Chief Financial Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£16.18 98.527 (personal contribution)
	£16.18 230.682 (personal contribution)
	£16.18 172.780 (personal contribution)
	£16.18 98.514 (personal contribution)
	£16.18 230.669 (personal contribution)
	£16.18 172.780 (personal contribution)
c) Price(s) and volume(s)	£16.18 98.527 (matching shares)
	£16.18 230.682 (matching shares)
	£16.18 172.780 (matching shares)
	£16.18 98.514 (matching shares)
	£16.18 230.669 (matching shares)
	£16.18 172.780 (matching shares)
d) Aggregated information	
Aggregated volume Price	2,007.904

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	£16.18
e) Date of the transaction	2017-07-14
f) Place of the transaction	n/a
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£16.18 36.169 (personal contribution)
	£16.18 85.292 (personal contribution)
	£16.18 62.593 (personal contribution)
	£16.18 36.169 (personal contribution)
	£16.18 85.292 (personal contribution)
	£16.18 62.582 (personal contribution)
c) Price(s) and volume(s)	£16.18 36.169 (matching shares)
	£16.18 85.292 (matching shares)
	£16.18 62.593 (matching shares)
	£16.18 36.169 (matching shares)
	£16.18 85.292 (matching shares)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.18 62.582 (matching shares)

Aggregated information

- d) Aggregated volume Price 736.194
 £16.18
 e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
 b) Position/status President, Global Pharmaceuticals
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
- b) Nature of the transaction
- | Price(s) | Volume(s) |
|----------|---------------------------------|
| £16.18 | 170.501 (personal contribution) |
| £16.18 | 201.553 (personal contribution) |
| £16.18 | 173.006 (personal contribution) |
| £16.18 | 201.553 (personal contribution) |
| £16.18 | 172.994 (personal contribution) |
- c) Price(s) and volume(s)
- | | |
|--------|---------------------------|
| £16.18 | 170.501 (matching shares) |
| £16.18 | 201.553 (matching shares) |
| £16.18 | 173.006 (matching shares) |
| £16.18 | 201.553 (matching shares) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£16.18 172.994 (matching shares)

Aggregated information

- d) Aggregated volume Price 1,839.214
 £16.18
- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare
- c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depository Shares ('ADSs')
 ISIN: US37733W1053
 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 \$42.50 70.929 (personal contribution)
 \$42.50 70.929 (matching shares)

Aggregated information

- d) Aggregated volume Price 141.858
 \$42.50
- e) Date of the transaction 2017-07-14
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of instrument;
 3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)
 has been conducted

Ordinary shares of 25 pence each
 ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest in Ordinary
 Shares following the re-investment of
 dividends paid to shareholders on 13 July
 2017 on Ordinary Shares held in the
 Company's 2009 Deferred Annual Bonus
 Plan.

Price(s) Volume(s)

£16.18 57.960 (personal contribution)

£16.18 108.550 (personal contribution)

£16.18 78.775 (personal contribution)

£16.18 57.960 (personal contribution)

£16.18 108.550 (personal contribution)

£16.18 78.763 (personal contribution)

c) Price(s) and volume(s)

£16.18 57.960 (matching shares)

£16.18 108.550 (matching shares)

£16.18 78.775 (matching shares)

£16.18 57.960 (matching shares)

£16.18 108.550 (matching shares)

£16.18 78.763 (matching shares)

Aggregated information

d)

Aggregated volume Price

981.116

£16.18

e) Date of the transaction

2017-07-14

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Ms C Thomas

b) Position/status

SVP, Human Resources

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’)
b) Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£16.18 78.015 (personal contribution)
	£16.18 158.805 (personal contribution)
	£16.18 118.568 (personal contribution)
	£16.18 78.002 (personal contribution)
	£16.18 158.805 (personal contribution)
	£16.18 118.568 (personal contribution)
c) Price(s) and volume(s)	
	£16.18 78.015 (matching shares)
	£16.18 158.805 (matching shares)
	£16.18 118.568 (matching shares)
	£16.18 78.002 (matching shares)
	£16.18 158.805 (matching shares)
	£16.18 118.568 (matching shares)
d) Aggregated information	
Aggregated volume Price	1,421.526 £16.18
e) Date of the transaction	2017-07-14
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status President, Global Affairs
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')														
b) Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.														
c) Price(s) and volume(s)	<table border="0" style="width: 100%;"> <thead> <tr> <th style="text-align: left;">Price(s)</th> <th style="text-align: left;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£16.18</td> <td>52.988 (personal contribution)</td> </tr> <tr> <td>£16.18</td> <td>97.162 (personal contribution)</td> </tr> <tr> <td>£16.18</td> <td>74.644 (personal contribution)</td> </tr> <tr> <td>£16.18</td> <td>52.988 (matching shares)</td> </tr> <tr> <td>£16.18</td> <td>97.162 (matching shares)</td> </tr> <tr> <td>£16.18</td> <td>74.644 matching shares)</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£16.18	52.988 (personal contribution)	£16.18	97.162 (personal contribution)	£16.18	74.644 (personal contribution)	£16.18	52.988 (matching shares)	£16.18	97.162 (matching shares)	£16.18	74.644 matching shares)
Price(s)	Volume(s)														
£16.18	52.988 (personal contribution)														
£16.18	97.162 (personal contribution)														
£16.18	74.644 (personal contribution)														
£16.18	52.988 (matching shares)														
£16.18	97.162 (matching shares)														
£16.18	74.644 matching shares)														
d) Aggregated information	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%;">Aggregated volume</td> <td>449.588</td> </tr> <tr> <td>Price</td> <td>£16.18</td> </tr> </table>	Aggregated volume	449.588	Price	£16.18										
Aggregated volume	449.588														
Price	£16.18														
e) Date of the transaction	2017-07-14														
f) Place of the transaction	n/a														

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D E Troy
 - b) Position/status SVP & General Counsel
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of instrument;
 3. (ii) each type of transaction; (iii) each date; and (iv) each place where
 transaction(s) has been conducted

- a) Description of the financial instrument American Depository Shares ('ADSs')
 ISIN: US37733W1053
 Increase in notional interest in ADSs
 following the re-investment of dividends
 paid to shareholders on 13 July 2017 on
 ADSs held in the Company's 2009
 Deferred Annual Bonus Plan.
- b) Nature of the transaction

Price(s)	Volume(s)
\$42.50	40.363 (personal contribution)
\$42.50	90.880 (personal contribution)
\$42.50	75.270 (personal contribution)
\$42.50	40.363 (personal contribution)
\$42.50	90.880 (personal contribution)
\$42.50	75.258 (personal contribution)

- c) Price(s) and volume(s)
- | | |
|---------|--------------------------|
| \$42.50 | 40.363 (matching shares) |
| \$42.50 | 90.880 (matching shares) |
| \$42.50 | 75.270 (matching shares) |
| \$42.50 | 40.363 (matching shares) |
| \$42.50 | 90.880 (matching shares) |
| \$42.50 | 75.258 (matching shares) |

- d) Aggregated information
 Aggregated volume Price 826.028
 \$42.50

- e) Date of the transaction 2017-07-14
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Dr P J T Vallance
 b) Position/status President, R&D

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’)
	ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£16.18 114.838 (personal contribution)
	£16.18 186.805 (personal contribution)
	£16.18 128.784 (personal contribution)
	£16.18 114.838 (personal contribution)
	£16.18 186.805 (personal contribution)
	£16.18 128.784 (personal contribution)
c) Price(s) and volume(s)	
	£16.18 114.838 (matching shares)
	£16.18 186.805 (matching shares)
	£16.18 128.784 (matching shares)
	£16.18 114.838 (matching shares)
	£16.18 186.805 (matching shares)
	£16.18 128.784 (matching shares)
d) Aggregated information	
Aggregated volume	1,721.708
Price	£16.18
e) Date of the transaction	2017-07-14
f) Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 17, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc